Prof. Irmela Jeremias is a pediatrician at the Hauner Children’s Hospital of LMU and a scientist at Helmholtz München. For her research on new targets to fight leukemia, she received a Reinhart Koselleck grant from the German Research Foundation (DFG). This grant supports highly innovative and promising projects. Her project aims to “Identify new targeted cancer therapies using in vivo CRISPR/Cas9 dropout screens in PDX models”.
The European Research Council has awarded the LMU chemist a grant for the preclinical development of a new drug for treating leukemia in high-risk patients.
Lies weiter
The formation of the biotech spinoff RNhale can be traced back to Professor Olivia Merkel’s groundbreaking research
Lies weiter
Nucleic acids in the form of siRNA, antisense oligonucleotides or mRNA are currently explored as new promising modalities in the
Lies weiter
EpiCure, eine Firmenidee, die auf Ausgründung wartet, gehört mir ihrem Konzept zu den 5 Siegern…
Lies weiter
Eisbach Bio GmbH (“Eisbach” or the “Company”), a privately-held clinical-stage biotechnology company pioneering cancer medicines leveraging synthetic lethality,
Lies weiter
Die QuGen GmbH, gegründet von Thomas Carell und Pascal Giehr, bietet hoch-sensitive Long-read Sequenzierung (PacBio), Bisulfit-freie Sequenzierung von DNA-Methylierung und
Lies weiter